Compare Mesoblast Limited (MESO) vs TE Connectivity plc Ordinary Shares (TEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs TE Connectivity plc Ordinary Shares — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while TE Connectivity plc Ordinary Shares trades at $215.4 (market cap $62.49B). The key difference: TE Connectivity plc Ordinary Shares is far larger — about 34.5× Mesoblast Limited's market cap, and TE Connectivity plc Ordinary Shares pays a 1.45% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | TEL | |
|---|---|---|
Market Cap | $1.81B | $62.49B |
Volume | 240,620 | 1,845,947 |
Sector | Health | Technology |
52-Week High | $20.96 | $249.00 |
52-Week Low | $13.19 | $195.84 |
Typical Hold Time | 14 Days | — |
Enterprise Value | $1.89B | $66.88B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About TE Connectivity plc Ordinary Shares
TE Connectivity designs and manufactures connectivity and sensor solutions. Its products support transportation, energy networks, industrial automation, communications infrastructure, and medical technology.
Read more on TEL →
